Sneak peek at mCRPC OS results at this year's ASCO
Posted from InvestorVillage
"OS in mCRPC
Nice to see an ASCO Cabo abstract title that mentions overall survival.
• An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. (Abstract 5026)
Howard I. Scher "
This will be an important preview for COMET-I's results.
The rash of positive sounding ASCO abstracts might be the reason for the recent run-up. Does anyone know where Biobetter on Investorvillage is getting access to these abstracts? I didn't have much luck after a cursory scan of the ASCO site.
"OS in mCRPC"
"Nice to see an ASCO Cabo abstract title that mentions overall survival. "
I've said a number of times that they have been stingy with OS data. The only things we've seen are data from HCC and RCC. I agree with you that this will be very important and hopefully the data will be broken out in terms of prior treatment, ECOG status, visceral mets, etc.
"I am particularly pleased the Dr Scher is making this presentation." I saw that too. I would say that if one had to pick the single most influential authority on CRPC, he's the guy. He has coauthored a number of the recent journal articles, but this is his first higher profile outing in a while. He does not back losers. The last horse he took to the finish line was Abiraterone.